Empowering Evidence Generation: Leveraging Commercial Data Infrastructure in Clinical Drug Development
Leveraging Commercial Data Infrastructure in Clinical Drug Development is the greatest connectivity we can have in the current time. The role of commercial data infrastructure is becoming increasingly pivotal. As pharmaceutical companies strive to address unmet medical needs, especially in rare disease indications, the ability to generate robust evidence through advanced data analytics is crucial. This approach not only enhances understanding of disease progression and patient outcomes but also accelerates scientific discoveries, ultimately leading to the successful launch of innovative therapies.
By leveraging comprehensive commercial data infrastructures, the industry can improve clinical trial design, optimize patient recruitment, and provide critical insights that support the entire drug development lifecycle. This integration of data-driven strategies marks a significant shift towards more efficient and effective pharmaceutical development, ensuring that novel treatments reach the patients who need them most.
With insider expertise, Nazim has established himself in commercial data analytics and forecasting, particularly in the pharmaceutical industry focusing on rare disease indications with significant unmet needs. His contributions at PharmaACE were pivotal in the commercial launch of a groundbreaking oncology drug, specifically targeting patients with KRAS G12C mutated non-small cell lung cancer—a demographic previously without an approved therapy.
At PharmaACE, Nazim’s achievements include leading analytics and forecasting workstreams for a first-in-class oncology drug, crucial for its commercial launch. By analyzing patient journeys using specialty pharmacy and medical claims data, he enhanced forecast model accuracy by 4% quarter-over-quarter through improved model assumptions.
Reportedly, Nazim also developed and promoted the adoption of a weekly product performance dashboard, strengthening alignment among sales, marketing, finance, and competitive intelligence teams. Furthermore, he improved physician reach by 15% in top deciles through a meticulously developed report tracking physician and account performance relative to market potential. By utilizing multiple datasets to understand prescribing behavior, he enhanced physician targeting lists by 25%, enabling accurate planning of quarterly goals for a newly launched oncology drug with datasets that provided 30% better coverage.
Currently, at Pliant Therapeutics, Nazim leads commercial data and forecasting capabilities for idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). One of his key projects involved establishing in-house commercial data infrastructure, resulting in cost savings of over $300,000 and enabling future scalability. Through the study of patient journeys spanning 4-5 years, he improved his understanding of treatment gaps in these rare diseases. Nazim's work utilizes commercial data to answer critical questions in clinical development, such as identifying key opinion leaders for patient recruitment and understanding patient comorbidities, and patient outcomes for extended periods. His leadership extends to launching and leading all aspects of IPF indication forecasting, enhancing market and competitor dynamics understanding. By developing real-world data capabilities, he informs forecast assumptions and supports cross-functional analytics related to new indication opportunities and evidence generation. He also informs study design and patient eligibility for non-fibrosing ILD subtypes using closed claims data.
His contributions extend to several influential research papers. In "Improving Understanding and Treatment of Rare Diseases through Real-World Data," he highlights the role of real-world data in enhancing disease understanding and accelerating scientific discoveries. His paper "Analytical Models for Physician Segmentation in the Pharmaceutical Industry: A Review and Evaluation" discusses innovative methods to improve accuracy in identifying key opinion leaders in rare diseases. In "Improving Health Outcomes in Frail Elderly: A Comprehensive Review of Measures and Recommendations," he emphasizes early identification and intervention to improve health outcomes for frail elderly individuals.
His work, "Evolution of Datasets and Methodologies for Measuring Patient Outcomes in Healthcare: A Comprehensive Review," details the transition from paper-based records to electronic health records and the importance of real-world data analyses. Finally, "Improving Diversity in Clinical Trials: Identifying Gaps and the Role of Real-World Data" evaluates the role of real-world data in promoting diversity in clinical trials and ensuring research generalizability.
Nazim’s insights underscore the importance of real-world datasets in enhancing disease understanding, providing necessary insights for clinical development, and ultimately improving patient outcomes. He advocates for early investment in commercial data infrastructure to accelerate scientific discoveries, emphasizing the unique needs of each disease indication and the critical role of real-world data analytics in the successful launch of pharmaceutical drugs. By building scalable and comprehensive data infrastructures, pharmaceutical companies can validate different metrics and ensure successful drug launches. Nazim Haider’s work exemplifies the transformative impact of advanced analytics and forecasting in the pharmaceutical industry.
